Immune Systems Advisor

Analysis  of COVID death data from the Centers for Disease Control and Prevention (CDC) in recent weeks found nearly 9 in 10 COVID deaths are reported among the 65 and older age demographic. As of the week ending Dec. 3, 2022, 92.6 percent of deaths are among people above 65 years old. Statistics reveal over 800,000 deaths among people ages 65 and older since the pandemic began, accounting for 75 percent of all COVID deaths to date. A  study  conducted on the older population suggests the severity and outcome of COVID-19 largely depend on a patient’s age. Adults 65 years of age and older represent 80 percent of all hospitalizations, and have a greater risk of death than people under the age of 65. Researchers  believe  that age-related decline and weakening of immune function are key factors contributing to the heightened vulnerability to severe COVID-19 outcomes in older adults. Of the deaths observed in older populations, the majority were witnessed in pa...

Melbourne, Australia; May 31 and New York, USA; May 30, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on survival outcomes from the randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) and plans for a pivotal trial with collaborative investigators.  Through the initial 90 days, remestemcel-L reduced mortality by 48% compared to controls in a prespecified analysis of 123 patients below age 65 (26% vs 44%, p=0.038),(1,2) but not in 97 patients over age 65, as previously reported. In an exploratory analysis in patients under age 65 who also received dexamethasone as part of their standard of care, remestemcel-L reduced 90-day mortality by 77% compared to controls (14% vs 48%, p=0.0037).(1,2) These early survival outcomes in the remestemcelL group relative to controls were maintained at lat...

August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy . PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. PCS consists of sequelae in one-third of COVID-19 patients and could potentially be permanent. The U.S. government estimated that between 7.7 to 23 million people are suffering from PCS in the United States. In Asia, PCS prevalence reaches 51%. Symptoms of PCS include breathlessness, persistent cough, fatigue, pain, brain fog, anxiety, depression, palpitations, dizziness, weakness, and sleep problems. ...